GHRP-6
Reviewed
Short answer
GHRP-6 is a real peptide made of six amino acids. Small studies in people found short-term changes in growth hormone. They did not show lasting muscle gain, fat loss, recovery, anti-aging, or other health benefits. No FDA-approved human GHRP-6 product was identified in the U.S. databases checked. FDA lists safety concerns for compounding, and WADA prohibits GHRP-6 at all times.
The Peptide Field explains research. Its pages are not independently medically reviewed, and they do not diagnose, prescribe, or recommend treatment.
Read the study findingsAlso known as Growth hormone-releasing peptide 6 · Growth hormone-releasing hexapeptide · SKF-110679
Part of Growth hormone peptides
Compared with Ipamorelin
Legal status Is GHRP-6 legal? See the status table
Study and product details
What it is
GHRP-6 is a short chain of six amino acids, the small building blocks that make peptides. FDA's identity record lists the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. It is designed to affect growth-hormone release. A growth-hormone response is a body measurement. It is not proof of a lasting health benefit.
Type of peptide: Growth hormone-releasing peptide. This describes what the substance is or how it works. It does not show that it is safe, effective, or approved.
What has been studied?
- Unclear: There is not enough reliable detail about the product or research to judge.
- Moderate: Useful evidence exists, but important limits remain.
- Limited: Research is too small or incomplete, or does not directly answer this question.
Small studies measured short-term hormone responses. They did not establish muscle gain, fat loss, recovery, or other lasting health outcomes.
Small studies in healthy men show a short-term growth-hormone response. One small early study measured how GHRP-6 moved through the body.
FDA lists possible immune reactions from peptide impurities or aggregation, plus possible cortisol and blood-sugar effects. Human studies are too small and brief to show uncommon or long-term harms.
FDA identity records do not establish finished-product quality or approval. Compounded and online products need separate evidence.
Products with the same ingredient can differ.
The ingredient name does not tell you everything about a product. Check its other ingredients, its form, how it enters the body, and the use and people covered by the research or approval.
None identified in the United States.
- Research on growth-hormone release and human exposure
Have a lab test report (COA) for a product sold under this name? Check what the report shows in 10 questions
Not sure if a product sold under this name is a prescription, compounded, or research-only vial? Sort it in 5 questions
What studies found
Small human studies show short-term hormone effects. In 17 healthy men, GHRP-6 increased growth hormone for a short time. Another study in 9 healthy men found that blocking a body signal called GHRH greatly reduced the response. An early study in 9 healthy men measured GHRP-6 exposure in the body. These studies measured hormones and exposure, not muscle gain, fat loss, recovery, or long-term health.
These studies do not show that GHRP-6 builds muscle, burns fat, speeds recovery, slows aging, or treats a health condition. The studies were small, short, and mainly in healthy men. One study changed the body's GHRH signal to test how the hormone response works. It was not a treatment study. No FDA-approved human GHRP-6 product was identified in the checked U.S. databases as of August 30, 2026. This is a dated database finding, not a claim about every country or future record.
Which products do these findings apply to?
FDA's identity record describes the GHRP-6 molecule, not a finished drug product. FDA lists GHRP-6 in compounding safety reviews and in its current 503A category list. Products sold online or made by a compounder need separate proof of identity, quality, and approval.
GHRP-6 side effects and safety: what FDA has said
This page has no trial or drug-label side-effect table for GHRP-6. FDA keeps a page of bulk substances that may be risky when a pharmacy mixes (compounds) them. Here is what that page says about GHRP-6, in plain words.
- FDA found limited safety information. The data it has show concerns, including a possible effect on cortisol, a stress hormone.
- FDA also names higher blood sugar, because the body may respond less to insulin.
- The body's immune system may react against it. FDA says this risk depends on how it is given.
- The peptide may clump together, which adds to that risk.
- Making it may leave unwanted peptide by-products in the product.
These points come from FDA's review of compounded drugs. They are not a full list of side effects. Having no reports does not mean a product is safe.
Read FDA's exact words
Growth hormone releasing peptide-6 (GHRP-6): “Compounded drugs containing GHRP-6 may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has identified limited safety-related information, but the available data reveal safety concerns including potential effect on cortisol and increase in blood glucose due to decreases in insulin sensitivity.”
Source: FDA, Certain bulk drug substances for use in compounding that may present significant safety risks , page dated .
Compare side-effect data across peptides
Report a side effect
You can report a suspected side effect to the FDA at 1-800-FDA-1088 or through FDA MedWatch . If a reaction feels serious, get medical care first.
FDA page checked .
Fact checks
6 statements checked. Read what the results mean.
“GHRP-6 is a six-amino-acid peptide.”
FDA's identity record lists GHRP-6 as a hexapeptide, which means six amino acids, and gives its sequence. An identity record does not prove approval, quality, or equivalence between products.
- What this answer is based on
- Official record or product label
- Limits of this answer
- The FDA-identified GHRP-6 molecule only. This identity fact does not cover every product sold under the name.
Sources for this fact check (1)
“GHRP-6 can raise growth hormone in short human studies.”
Small studies in healthy men measured short-term increases in growth hormone after GHRP-6. One study found that the response depended in large part on GHRH, another body signal. These are hormone measurements, not proof of treatment benefit.
- What this answer is based on
- Studies of body changes in people
- Limits of this answer
- Small, short studies in healthy men; hormone response only, not muscle, fat loss, recovery, or other health outcomes.
Sources for this fact check (2)
“A growth-hormone response proves that GHRP-6 builds muscle or burns fat.”
A hormone response is not the same as a lasting health outcome. The reviewed human studies did not establish muscle gain or fat loss.
- What this answer is based on
- No reliable studies showing this health result in people
- Limits of this answer
- Muscle, fat-loss, and other lasting outcomes; the reviewed studies measured hormones or exposure only.
Sources for this fact check (2)
Show 3 more fact checks
“GHRP-6 is FDA-approved in the United States.”
No FDA-approved human GHRP-6 product was identified in the checked U.S. databases as of August 30, 2026. FDA's substance identity record does not mean approval. This is a dated database finding, not a claim about every country or future record.
- What this answer is based on
- Official record or product label
- Limits of this answer
- U.S. human drug records checked on August 30, 2026.
Sources for this fact check (2)
“A compounded GHRP-6 product is FDA-approved.”
FDA says it does not approve compounded drugs. Its current 503A list puts GHRP-6 in Category 3. This means the nomination did not have enough support. FDA also lists safety concerns for 503B compounding. A 2019 warning letter said GHRP-6 did not meet the 503A rules in that case.
- What this answer is based on
- Official record or product label
- Limits of this answer
- U.S. FDA records about compounded GHRP-6, checked August 30, 2026. This is not legal advice about one product.
Sources for this fact check (5)
“GHRP-6 is allowed in tested sport.”
The 2026 WADA Prohibited List names GHRP-6 under growth hormone-releasing factors. WADA prohibits it at all times, both in and out of competition.
- What this answer is based on
- Official record or product label
- Limits of this answer
- Athletes subject to the 2026 WADA Prohibited List; rules can differ by sport and organization.
Sources for this fact check (1)
Questions people ask about GHRP-6
FDA's page on risky compounding substances says this about GHRP-6. FDA found limited safety information. The data it has show concerns, including a possible effect on cortisol, a stress hormone. FDA also names higher blood sugar, because the body may respond less to insulin. The body's immune system may react against it. FDA says this risk depends on how it is given. The peptide may clump together, which adds to that risk. Making it may leave unwanted peptide by-products in the product. These points come from FDA's review of compounded drugs. They are not a full list of side effects.
Risks and safety limits
FDA lists GHRP-6 among substances that may present safety risks in compounding. FDA notes possible immune reactions from peptide impurities or aggregation, limited safety information, and possible cortisol or blood-sugar effects. This guide gives no dosing, injection, sourcing, or treatment instructions.
The 2026 WADA Prohibited List names GHRP-6 under growth hormone-releasing factors. It is prohibited in and out of competition. This page is not personal clearance. Athletes must check the current rules that apply to them.
Reviewed .Check the rules for athletes ↗Read the official rules ↗Terms used in the studies
- peptide
- a short chain of amino acids
- amino acid
- a small building block that makes peptides and proteins
- molecule
- one specific chemical substance
- outcome
- what the study measured
- compounded
- made for one patient by a pharmacy, or in batches by a permitted outsourcing facility; a compounded drug is not FDA-approved
- mechanism
- how a substance may cause a body change
- biomarker
- a body or lab measurement, not automatically a health benefit
- human pharmacology
- a study of how a substance changes the body in people
Read the sources
Show 11 sources
Review history
Initial brief reviewed FDA identity and compounding records, small human hormone and exposure studies, the FDA approval database, and the 2026 World Anti-Doping Agency list.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.
Report a factual error